{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:09:07Z","timestamp":1790179747677,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jgar.2026.07.009","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:08:06Z","timestamp":1784822886000},"page":"316-323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Relebactam enhances the activity of imipenem against Burkholderia cepacia complex isolates"],"prefix":"10.1016","volume":"50","author":[{"given":"Lianzhu","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Mane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Hilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Motyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6271-2597","authenticated-orcid":false,"given":"Henry S.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"McKenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3941-6589","authenticated-orcid":false,"given":"Mark","family":"Estabrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5942-9707","authenticated-orcid":false,"given":"C. Andrew","family":"DeRyke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1490-5455","authenticated-orcid":false,"given":"Katherine","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.07.009_bib0001","article-title":"Burkholderia cepacia","volume":"33","author":"Tavares","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.07.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1128\/jb.00441-23","article-title":"Cell envelope structural and functional contributions to antibiotic resistance in Burkholderia cenocepacia","volume":"206","author":"Hogan","year":"2024","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jgar.2026.07.009_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00927-19","article-title":"Regulation of virulence by two-component systems in pathogenic Burkholderia","volume":"88","author":"Schaefers","year":"2020","journal-title":"Infect Immun"},{"key":"10.1016\/j.jgar.2026.07.009_bib0004","doi-asserted-by":"crossref","unstructured":"Seelman SL, Bazaco MC, Wellman A, Hardy C, Fatica MK, Huang MJ, et al. Burkholderia cepacia. Epidemiol Infect. 2022;150:e154. doi:10.1017\/s0950268822000668.","DOI":"10.1017\/S0950268822000668"},{"key":"10.1016\/j.jgar.2026.07.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01332-21","article-title":"Activity of imipenem-relebactam against multidrug- and extensively drug-resistant Burkholderia cepacia complex and Burkholderia gladioli","volume":"65","author":"Becka","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.07.009_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2307503","article-title":"Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy","volume":"56","author":"Guti\u00e9rrez Santana","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.jgar.2026.07.009_bib0008","article-title":"Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation","volume":"2016","author":"Horsley","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jgar.2026.07.009_bib0009","unstructured":"Network PCF. CF guidelines \u2013 Burkholderia cepacia. https:\/\/www.pencf.org.uk\/chest_problems\/burkholderia_cepacia.html. [Accessed April 20, 2026]."},{"key":"10.1016\/j.jgar.2026.07.009_bib0010","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1513\/AnnalsATS.201402-050AS","article-title":"Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections","volume":"11","author":"Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jgar.2026.07.009_bib0011","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/antibiotics11050612","article-title":"Antibiotic therapy for difficult-to-treat infections in lung transplant recipients: a practical approach","volume":"11","author":"van den Bogaart","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.07.009_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107014","article-title":"Antimicrobial surveillance: a 20-year history of the SMART approach to addressing global antimicrobial resistance into the future","volume":"62","author":"Cant\u00f3n","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.07.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.009_bib0014","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ijid.2020.07.046","article-title":"Management of intra-abdominal-infections: 2017 World Society of Emergency Surgery guidelines summary focused on remote areas and low-income nations","volume":"99","author":"Perrone","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.009_bib0015","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy\/Healthcare Infection Society\/British Infection Association Joint Working Party","volume":"73","author":"Hawkey","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.07.009_bib0016","unstructured":"RECARBRIO (imipenem\/cilastatin\/relebactam). Prescribing information. Merck Sharp & Dohme LLC, Rahway, NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/212819s002lbl.pdf. [Accessed September 19, 2025]."},{"key":"10.1016\/j.jgar.2026.07.009_bib0017","unstructured":"RECARBRIO (imipenem\/cilastatin\/relebactam). Summary of product characteristics. MSD B.V. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/recarbrio-epar-product-information_en.pdf. [Accessed September 19, 2025]."},{"key":"10.1016\/j.jgar.2026.07.009_bib0020","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00346-23","article-title":"In vitro and in vivo activity of cefiderocol against Achromobacter spp. And Burkholderia cepacia complex, including carbapenem-non-susceptible isolates","volume":"67","author":"Takemura","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.07.009_bib0021","series-title":"CLSI Standard M07","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Zimmer","year":"2024"},{"key":"10.1016\/j.jgar.2026.07.009_bib0022","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12866-023-02864-3","article-title":"Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020","volume":"23","author":"Hilbert","year":"2023","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jgar.2026.07.009_bib0023","article-title":"Burkholderia ubonensis meropenem resistance: insights into distinct properties of class A \u03b2-lactamases in Burkholderia cepacia complex and Burkholderia pseudomallei complex bacteria","volume":"11:e00592-20","author":"Somprasong","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.jgar.2026.07.009_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2025.101601","article-title":"In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: a systematic review","volume":"66","author":"Zomorodi","year":"2025","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.jgar.2026.07.009_bib0025","doi-asserted-by":"crossref","first-page":"7602","DOI":"10.1128\/AAC.01068-15","article-title":"Cell wall recycling-linked coregulation of AmpC and PenB \u03b2-lactamases through ampD mutations in Burkholderia cenocepacia","volume":"59","author":"Hwang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.07.009_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02577-17","article-title":"In vivo efficacy of relebactam (MK-7655) in combination with imipenem-cilastatin in murine infection models","volume":"62","author":"Powles","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.07.009_bib0027","article-title":"Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a \u03b2-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants","volume":"62","author":"Rhee","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.07.009_bib0028","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Antimicrobial susceptibility testing of Burkholderia cepacia complex (BCC). https:\/\/www.eucast.org\/eucastguidancedocuments. [Accessed June 10, 2025]."},{"key":"10.1016\/j.jgar.2026.07.009_bib0029","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/cid\/cix559","article-title":"A 17-year nationwide study of Burkholderia cepacia complex bloodstream infections among patients in the United States Veterans Health Administration","volume":"65","author":"El Chakhtoura","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.07.009_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2026.103158","article-title":"Burkholderia cepacia complex infections beyond hospital outbreaks: a 22-year analysis of clinical characteristics, antimicrobial resistance, and mortality predictors","volume":"19","author":"Alwazzeh","year":"2026","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2026.07.009_bib0031","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01595-19","article-title":"In vitro activities of \u03b2-lactam-\u03b2-lactamase inhibitor antimicrobial agents against cystic fibrosis Respiratory pathogens","volume":"64","author":"Caverly","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.07.009_bib0032","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s15010-025-02474-3","article-title":"Comparison of the in vitro activities and resistance mechanisms against imipenem-relebactam and ceftazidime-avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China","volume":"53","author":"Guo","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2026.07.009_bib0033","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/antibiotics12020217","article-title":"Antibiotic resistance in patients with cystic fibrosis: past, present, and future","volume":"12","author":"Perikleous","year":"2023","journal-title":"Antibiotics (Basel)"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:52:28Z","timestamp":1790178748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S2213716526001190"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.07.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relebactam enhances the activity of imipenem against Burkholderia cepacia complex isolates","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}